Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial

Several studies have shown that a large number of patients who are fulfilling the criteria for irritable bowel syndrome (IBS) are sensitive to gluten. The aim of this study was to evaluate the effect of a gluten-free diet on gastrointestinal symptoms in patients with IBS. In this double-blind random...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2015-06, Vol.7 (6), p.4542-4554
Main Authors: Shahbazkhani, Bijan, Sadeghi, Amirsaeid, Malekzadeh, Reza, Khatavi, Fatima, Etemadi, Mehrnoosh, Kalantri, Ebrahim, Rostami-Nejad, Mohammad, Rostami, Kamran
Format: Article
Language:English
Subjects:
Adult
Anxiety
Celiac Disease
Diet
Diet, Gluten-Free
Double-Blind Method
Female
Follow-Up Studies
Food
Gastroenterology
Gluten
gluten free diet
Glutens - administration & dosage
Glutens - adverse effects
Hospitals
Humans
IBS
Iran
Irritable bowel syndrome
Irritable Bowel Syndrome - diagnosis
Irritable Bowel Syndrome - etiology
Liver diseases
Male
Middle Aged
non-celiac gluten sensitivity
Nutrients
Patient Compliance
Research centers
Treatment Outcome
Visual Analog Scale
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several studies have shown that a large number of patients who are fulfilling the criteria for irritable bowel syndrome (IBS) are sensitive to gluten. The aim of this study was to evaluate the effect of a gluten-free diet on gastrointestinal symptoms in patients with IBS. In this double-blind randomized, placebo-controlled trial, 148 IBS patients fulfilling the Rome III criteria were enrolled between 2011 and 2013. However, only 72 out of the 148 commenced on a gluten-free diet for up to six weeks and completed the study; clinical symptoms were recorded biweekly using a standard visual analogue scale (VAS). In the second stage after six weeks, patients whose symptoms improved to an acceptable level were randomly divided into two groups; patients either received packages containing powdered gluten (35 cases) or patients received placebo (gluten free powder) (37 cases). Overall, the symptomatic improvement was statistically different in the gluten-containing group compared with placebo group in 9 (25.7%), and 31 (83.8%) patients respectively (p < 0.001). A large number of patients labelled as irritable bowel syndrome are sensitive to gluten. Using the term of IBS can therefore be misleading and may deviate and postpone the application of an effective and well-targeted treatment strategy in gluten sensitive patients.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu7064542